Roche, Novartis highlight intensifying rivalry in eye disease, MS

ZURICH (Reuters) - Swiss drugmakers Roche and Novartis underscored how their portfolios are increasingly clashing on the commercial battlefield, announcing on Wednesday new data on drugs aimed at capturing market share from each other. Roche said its port delivery system (PDS) requiring twice-yearly refills of a customised version of eye drug Lucentis was as good as monthly injections against blindness-causing macular degeneration, a market Novartis is also targeting with its new medicine..